ASN-FDA Collaboration Takes on Rare Kidney Disease

Patients, Industry, and Clinicians Work to Find Surrogate Endpoints for Hyperoxaluria Clinical Trials

Restricted access

Kristi Ouimet is hopeful her 15-year-old daughter will be admitted into a clinical trial of an experimental treatment for hyperoxaluria, a rare kidney condition that causes formation of painful and even life-threatening kidney stones. If she is enrolled in the trial, it will require a monthly commute from California to Minnesota for 2 years. But she’s not deterred. She’s already managed 2 years of a 6-day-per-week commute for 4 hours of daily dialysis plus 7 days a week of peritoneal dialysis for her younger son, who is also affected by hyperoxaluria and required a kidney and liver transplant.

“[If] driving